Kan Min, Shi Hai-Yan, Han Bing, Wu Yue-E, Li Qian, Guo Zi-Xuan, Li Xue, Hao Guo-Xiang, Zheng Yi, Su Le-Qun, Huang Xin, Sui Zhong-Guo, Zhao Wei
Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.00779-20.
The pharmacological activity of ceftriaxone depends on the unbound concentration. However, direct measurement of unbound concentrations is obstructive, and high individual variability of the unbound fraction of ceftriaxone was shown in children. We aim to evaluate and validate a method to predict unbound ceftriaxone concentrations in pediatric patients. Ninety-five pairs of concentrations (total and unbound) from 92 patients were measured by the bioanalysis method that we developed. The predictive performance of the three equations (empirical equation, disease-adapted equation, and multiple linear regression equation) was assessed by the mean absolute prediction error (MAPE), the mean prediction error (MPE), the proportions of the prediction error within ±30% () and ±50% (), and linear regression of predicted versus actual unbound levels (). The average total and unbound ceftriaxone concentrations were 126.18 ± 81.46 μg/ml and 18.82 ± 21.75 μg/ml, and the unbound fraction varied greatly from 4.75% to 39.97%. The MPE, MAPE, , , and of the empirical equation, disease equation, and multiple linear equation were 0.17 versus 0.00 versus 0.06, 0.24 versus 0.15 versus 0.27, 63.2% versus 89.5% versus 74.7%, 96.8% versus 97.9% versus 86.3%, and 0.8730 versus 0.9342 versus 0.9315, respectively. The disease-adapted equation showed the best predictive performance. We have developed and validated a bioanalysis method with one-step extraction pretreatment for the determination of total ceftriaxone concentrations, and a prediction equation of the unbound concentration is recommended. The proposed method can facilitate clinical practice and research on unbound ceftriaxone in children. (This study has been registered at ClinicalTrials.gov under identifier NCT03113344.).
头孢曲松的药理活性取决于游离浓度。然而,直接测量游离浓度具有阻碍性,并且在儿童中已显示头孢曲松游离分数存在高度个体差异。我们旨在评估和验证一种预测儿科患者头孢曲松游离浓度的方法。通过我们开发的生物分析方法测量了92名患者的95对浓度(总浓度和游离浓度)。通过平均绝对预测误差(MAPE)、平均预测误差(MPE)、预测误差在±30%()和±50%()范围内的比例以及预测游离水平与实际游离水平的线性回归()来评估三个方程(经验方程、疾病适应方程和多元线性回归方程)的预测性能。头孢曲松的平均总浓度和游离浓度分别为126.18±81.46μg/ml和18.82±21.75μg/ml,游离分数在4.75%至39.97%之间变化很大。经验方程、疾病方程和多元线性方程的MPE、MAPE、、和分别为0.17对0.00对0.06、0.24对0.15对0.27、63.2%对89.5%对74.7%、96.8%对97.9%对86.3%以及0.8730对0.9342对0.9315。疾病适应方程显示出最佳预测性能。我们开发并验证了一种采用一步萃取预处理的生物分析方法来测定头孢曲松总浓度,并推荐了游离浓度的预测方程。所提出的方法可促进儿童头孢曲松游离浓度的临床实践和研究。(本研究已在ClinicalTrials.gov上注册,标识符为NCT03113344。)